Advanced search
Start date
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Blockade of fear-induced antinociception with intra-amygdala infusion of midazolam: Influence of prior test experience

Full text
Baptista, Daniela [1, 2] ; Bussadori, Karina [1] ; Nunes-de-Souza, Ricardo Luiz [2, 3] ; Canto-de-Souza, Azair [1, 2]
Total Authors: 4
[1] Univ Fed Sao Carlos, CECH, Dept Psicol, Grp Psicobiol, BR-13565905 Sao Carlos, SP - Brazil
[2] Univ Fed Sao Carlos, UNESP, Programa Posgrad Ciencias Fisiol, BR-13565905 Sao Carlos, SP - Brazil
[3] Sao Paulo State Univ, UNESP, Pharmacol Lab, Sch Pharmaceut Sci, Araraquara, SP - Brazil
Total Affiliations: 3
Document type: Journal article
Source: Brain Research; v. 1294, p. 29-37, OCT 6 2009.
Web of Science Citations: 15

Intra-amygdala infusion of midazolam, a benzodiazepine receptor agonist, produces anxiolytic-like effects in mice when first exposed to the elevated plus-maze (EPM) and blocks antinociception induced in mice confined in the open arm of the EPM. However, benzodiazepines fail to alter anxiety in maze-experienced rodents, a phenomenon defined as ``one-trial tolerance{''} (OTT). The main purpose of the present study was to investigate whether intra-amygdala midazolam attenuates the open ann-induced antinociception (OAA) in maze-experienced mice. Nociception was assessed by the writhing test (intraperitoneal injection of 0.6% acetic acid). In Experiment 1, nociception was recorded in maze-experienced mice without prior drug treatment. Experiment 2 investigated the effects of systemic midazolam (0.5, 1.0 and 2.0 mg/kg, s.c.), injected before EPM trial 2, on OAA in maze-experienced mice. in Experiment 3, the effects on OAA of intra-amygdala midazolam (30 nmol/0.1 mu l), injected before trial 1 (maze-naive) or before trial 2 (maze-experienced), were observed. The effects on OAA of intra-amygdala midazolam injected before trial 1 and trial 2 were also investigated (Experiment 4). The results showed that OAA remained unchanged in maze-experienced mice and was insensitive to systemic midazolam. However, intra-amygdala midazolam attenuated OAA in maze-naive mice, but not in maze-experienced mice. Even when given before both trial 1 and trial 2, intra-amygdala midazolam failed to alter OAA in maze-experienced mice. Taken together, these results confirm that the GABA(A)/benzodiazepine receptor complex located within the amygdala plays a role in OAA in maze-naive mice. The lack of effects following systemic or intra-amygdala midazolam on OAA in maze-experienced mice suggests that the OTT is also observed in the modulation of nociception and that the GABA(A)/benzodiazepine receptor located within this limbic forebrain structure participates in this process. (C) 2009 Elsevier B.V. All rights reserved. (AU)

FAPESP's process: 06/06855-4 - Effects of systemic and intra-amygdala injections of midazolam on fear-induced antinociception in maze-experienced mice
Grantee:Daniela Baptista de Souza
Support Opportunities: Scholarships in Brazil - Scientific Initiation